Literature DB >> 10444118

Desmopressin in the treatment of nocturnal polyuria in the male.

A Cannon1, P G Carter, A A McConnell, P Abrams.   

Abstract

OBJECTIVES: To assess whether desmopressin (1-desamino 8-d-arginine vasopressin) is safe and effective in the treatment of nocturnal polyuria in elderly men. PATIENTS AND METHODS: Twenty men (age 52-80 years) complaining of nocturia were found to have nocturnal polyuria, determined from frequency-volume charts and defined as the production of >33% of the 24 h urine volume overnight, averaged over a 1-week period. In a double-blind study of cross-over design, a 1-week placebo run-in period was followed by two 2-week periods of placebo or 20 microg intranasal desmopressin, and ended with an open 2-week treatment period with 40 microg desmopressin.
RESULTS: Desmopressin caused a significant reduction in nocturnal urine volume and the percentage of urine passed at night, but the reduction in nocturnal frequency was only significant during treatment with 40 microg desmopressin. Four patients on desmopressin experienced side-effects, three of which were thought to be due to fluid retention.
CONCLUSION: Desmopressin is an effective treatment for nocturnal polyuria in some elderly men. However, it can cause fluid retention and should not be given to patients with cardiac failure. Those undergoing treatment must be closely monitored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444118     DOI: 10.1046/j.1464-410x.1999.00125.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Authors:  Asa Rembratt; Charlotte Graugaard-Jensen; Thomas Senderovitz; Jens Peter Norgaard; Jens Christian Djurhuus
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

2.  Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden.

Authors:  Rickard Ljung
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

Review 3.  Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.

Authors:  Huantao Zong; Chenchen Yang; Xiaoxia Peng; Yong Zhang
Journal:  Int Urol Nephrol       Date:  2011-09-07       Impact factor: 2.370

Review 4.  [Treatment of nocturia in men with desmopressin].

Authors:  S Mühlstädt
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

5.  A retrospective review of the ambulatory blood pressure patterns and diurnal urine production in subgroups of spinal cord injured patients.

Authors:  M Y Goh; E C K Wong; M S Millard; D J Brown; C J O'Callaghan
Journal:  Spinal Cord       Date:  2014-11-11       Impact factor: 2.772

6.  Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.

Authors:  Henrik Agersø; Lotte Seiding Larsen; Anders Riis; Ulf Lövgren; Mats O Karlsson; Thomas Senderovitz
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

Review 7.  Desmopressin for treating nocturia in men.

Authors:  Julia Han; Jae Hung Jung; Caitlin J Bakker; Mark H Ebell; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-10-21

Review 8.  Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature.

Authors:  Diaa-Eldin Taha; Omar M Aboumarzouk; Ahmed A Shokeir
Journal:  Arab J Urol       Date:  2018-07-25

Review 9.  Korean guideline of desmopressin for the treatment of nocturia in men.

Authors:  Eu Chang Hwang; Hyun Jin Jung; Mi Ah Han; Myung Ha Kim; Seong Hyeon Yu; Hyun Cheol Jeong; Jun Seok Kim; Sung Hyun Paick; Jeong Kyun Yeo; Jae Hung Jung
Journal:  Investig Clin Urol       Date:  2022-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.